Loading…
High Biocompatibility, MRI Enhancement, and Dual Chemo- and Thermal-Therapy of Curcumin-Encapsulated Alginate/Fe 3 O 4 Nanoparticles
(1) Background: Magnetite (Fe O ) nanoparticles have great potential for biomedical applications, including hyperthermia and magnetic resonance imaging. In this study, we aimed to identify the biological activity of nanoconjugates composed of superparamagnetic Fe O nanoparticles coated with alginate...
Saved in:
Published in: | Pharmaceutics 2023-05, Vol.15 (5) |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | (1) Background: Magnetite (Fe
O
) nanoparticles have great potential for biomedical applications, including hyperthermia and magnetic resonance imaging. In this study, we aimed to identify the biological activity of nanoconjugates composed of superparamagnetic Fe
O
nanoparticles coated with alginate and curcumin (Fe
O
/Cur@ALG) in cancer cells. (2) Methods: The nanoparticles were evaluated for the biocompatibility and toxicity on mice. The MRI enhancement and hyperthermia capacities of Fe
O
/Cur@ALG were determined in both in vitro and in vivo sarcoma models. (3) Results: The results show that the magnetite nanoparticles exhibit high biocompatibility and low toxicity in mice at Fe
O
concentrations up to 120 mg/kg when administered via intravenous injection. The Fe
O
/Cur@ALG nanoparticles enhance the magnetic resonance imaging contrast in cell cultures and tumor-bearing Swiss mice. The autofluorescence of curcumin also allowed us to observe the penetration of the nanoparticles into sarcoma 180 cells. In particular, the nanoconjugates synergistically inhibit the growth of sarcoma 180 tumors via magnetic heating and the anticancer effects of curcumin, both in vitro and in vivo. (4) Conclusions: Our study reveals that Fe
O
/Cur@ALG has a high potential for medicinal applications and should be further developed for cancer diagnosis and treatment. |
---|---|
ISSN: | 1999-4923 1999-4923 |
DOI: | 10.3390/pharmaceutics15051523 |